NCT00001683View on ClinicalTrials.gov

A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 1997

Study Completion Date

August 31, 2003

Conditions

LymphomaMelanomaNeoplasm MetastasisRenal Cell Carcinoma

Interventions

DRUG

COL-3

Trial Locations (1)

20892

National Cancer Institute (NCI), Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00001683 - A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer | Biotech Hunter | Biotech Hunter